PURPOSE MET dysregulation is an oncogenic driver in non–small-cell lung cancer
(NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients …

Introduction: Activation of the MET pathway through MET amplifications or mutations is
present in 3–4% of stage IV non-squamous non-small cell lung cancers (NSCLC). High MET …

Simple Summary In this narrative review, we discuss the development of capmatinib, a
reversible MET tyrosine kinase inhibitor that received approval for advanced non-small cell …

Introduction Numerous therapeutic agents specifically targeting the mesenchymal-epithelial
transition (MET) oncogene are being developed. Objective The aim of the current review …

Simple Summary MET is a receptor tyrosine kinase encoded by the MET proto-oncogene
that has a significant role in cancer cell progression. Several drugs targeting MET are under …

Background Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs
in 3%–4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable …

Background MET and AXL dysregulation is reported as a bypass mechanism driving tumour
progression in non-small cell lung cancer (NSCLC) with acquired resistance to epidermal …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

9520 Background: Capmatinib (INC280) has shown promising efficacy in patients (pts) with
MET exon 14 (METex14)–mutated NSCLC who were pretreated (cohort 4) or treatment (tx) …

9509 Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study,
capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who …